CN105596345A - Drug composition of cefoperazone sodium and sulbactam sodium - Google Patents
Drug composition of cefoperazone sodium and sulbactam sodium Download PDFInfo
- Publication number
- CN105596345A CN105596345A CN201610006351.2A CN201610006351A CN105596345A CN 105596345 A CN105596345 A CN 105596345A CN 201610006351 A CN201610006351 A CN 201610006351A CN 105596345 A CN105596345 A CN 105596345A
- Authority
- CN
- China
- Prior art keywords
- sodium
- sulbactam
- cefoperazone
- pharmaceutical composition
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Abstract
The invention discloses a drug composition of cefoperazone sodium and sulbactam sodium. The drug composition comprises cefoperazone sodium and sulbactam sodium, the mass ratio of cefoperazone sodium to sulbactam sodium is (1-2):1, the specific rotation of cefoperazone sodium ranges from minus 20 degrees to minus 24 degrees, and the specific rotation of sulbactam sodium ranges from 223 degrees to 228 degrees. The drug composition is prepared from cefoperazone sodium and sulbactam sodium which have the specific rotation, the drug stability can be improved, and safe medication can be achieved in clinic.
Description
Technical field
The present invention relates to field of medicaments, relate in particular a kind of drug regimen of cefoperazone sodium sulbactam sodiumThing.
Background technology
Cefoperazone sodium sulbactam sodium is compound formulation, and antibacterial activity, higher than cefoperazone sodium, is developed by PfizerCity, commodity are called sulperazone (Sulperazon). Sulbactam is that wide spectrum enzyme inhibitor has weak antibacterial activity simultaneously, to goldThe beta-lactamase that Portugal bacterium and most negative bacillus produce has powerful irreversible inhibitory action, but to some negative bacillusThe beta-lactam kinase inactive of Chromosome-encoded. Cefoperazone is a third generation cephalosporin, to stablizing of beta-lactamaseProperty poor, the two associating, not only negative bacillus is shown to obvious Synergistic antimicrobial activity, the antibacterial action after associating is independent head4 times of spore piperazine ketone.
The pharmaceutical composition of existing cefoperazone sodium sulbactam sodium mostly existence and stability deficiency, cannot protect clinicallyThe problem of reliable, the effective medication of card, thus patient is caused to sizable potential safety hazard.
Summary of the invention
The invention provides a kind of pharmaceutical composition and preparation thereof of cefoperazone sodium sulbactam sodium, this pharmaceutical composition adoptsCefoperazone sodium and the sulbactam of specific specific rotation make, and can improve medicine stability, make the clinical safe medication that is able to.
For solving above-mentioned technical problem, the present invention by the following technical solutions:
A pharmaceutical composition for cefoperazone sodium sulbactam sodium, comprises sulbactam and specific rotation and is-20 °～-24 °Cefoperazone sodium, the mass ratio of cefoperazone sodium and sulbactam is 1～2:1.
The pharmaceutical composition of cefoperazone sodium sulbactam sodium of the present invention is-20 °～-24 ° by sulbactam and specific rotationCefoperazone sodium evenly mixed powder form, the process of mixed powder is to carry out in existing preparation laboratory, is existing technical process,Therefore repeat no more.
Further, the specific rotation of cefoperazone sodium is-22 °～-24 °.
The specific rotation of cefoperazone sodium is-24 °, and the mass ratio of cefoperazone sodium and sulbactam is 2:1.
Inventor, in the stability experiment of research cefoperazone sodium sulbactam sodium, chances on specific rotation differentThe stability difference of cefoperazone sodium sulbactam sodium, the efficiency of its degraded is also different. Selection specific rotation is the head of-20 °～-24 °Content and the purity of the cefoperazone sodium sulbactam sodium product that spore piperazine ketone sodium and sulbactam form are high, and can improve medicineStability, particularly clarity stability, than in commercially available cefoperazone sodium sulbactam sodium, clarity stability is better.
The specific rotation of sulbactam is+223 °～+ 228 °. Inventor finds to add relaxing of certain specific rotation scope simultaneouslyBatan sodium, also can help to improve medicine stability, improves content and the purity of cefoperazone sodium sulbactam sodium product.
The specific rotation of sulbactam is+223 °～+ 225 °.
The preparation method of cefoperazone sodium is: it is molten that (1) is added to cefoperazone acid acetone at 0-5 DEG C by SAS stirringIn liquid, pH value is controlled at 6.5-6.9; (2) after sodium acetate adds, then solution is warming up to 10-25 degree Celsius, by bicarbonateSodium solution stirs and is added in cefoperazone acid acetone soln, and pH value is controlled at 6.5-6.9; (3) react after complete decolorization filtering, pointIn three stages, the first stage, agitation and dropping entered acetone by filtrate temperature control at 18-20 DEG C, dripped 5-10min; Second stage, 18-20DEG C stir 30-60min, after crystal is separated out, continue agitation and dropping acetone, drip 10-15min; Phase III, 10-15 DEG C is stirredMix 30-60min, filtration washing obtains crystal; Wherein roar the rubbing of piperazine ketone acid of the molal quantity total amount of sodium acetate and sodium acid carbonate and headYou equate by number.
Before in step (2), dripping after SAS, heating up, also comprise standing step, time of repose is 20-40min。
The cefoperazone sodium itself that the preparation method of the cefoperazone sodium that the present invention adopts obtains is stable, is difficult for degraded, pointIt is also higher that dress preparation is deposited the clarity of solution stability of long period, meet national standard, and particle is large, product yieldHeight, can reach more than 94%, the specific rotation of the cefoperazone sodium preparing can be controlled at+264 °～+ 269 ° in.
In preparation process, this method adopts sodium acetate and sodium acid carbonate as salt forming agent, first selects sodium acetate as theOne salt forming agent, sodium acid carbonate, as the second salt forming agent, under certain temperature conditions, can obtain the product of high-load(more than 93.5wt%) and lower catabolite (0.5-2%). What sodium acetate played as the first salt forming agent act as controlMake the crystalline particle size of initial cefoperazone sodium, experiment discovery, sodium acetate can obtain as salt forming agent under certain conditionOarse-grained cefoperazone sodium crystal, but the yield obtaining is not high, and the clarity of product is bad, therefore in the present invention, woundThe property made first using sodium acetate as the first salt forming agent, then using sodium acid carbonate as the second salt forming agent, finally in the time of crystallization, acetic acidSodium obtains the oarse-grained nucleus of crystal as salt forming agent, obtains in the oarse-grained inducing action of crystal the cephalo that crystal size is largePiperazine ketone sodium, product purity is high, and yield can reach more than 93.5%, and specific rotation is at+264 °～+ 269 °.
The molfraction of sodium acetate is the 10-15% of cefoperazone acid, and the molfraction of sodium acid carbonate is cephalo ketone acid85-90%. Because adopt sodium acetate not high as the product yield of salt forming agent, therefore the molal quantity of sodium acetate cans be compared to bicarbonate mostThe molal quantity of sodium is few.
In step (3), first stage mixing speed is 300-350r/min.
In step (3), second stage mixing speed is 200-250r/min.
In step (3), phase III mixing speed is 100-150r/min.
The preparation method of sulbactam is: at (one) 20-25 DEG C, sulbactam is added to the mixed of sodium acetate and sodium acid carbonateClose in solution constantly and stir, and to control pH value of solution be 5.5-6.0; (2), after reaction finishes, add ethanol and constantly stir 10minAfter, use infrared radiation 3-5min simultaneously, continue to stir 30-60min and obtain crystal, wherein the molfraction of sodium acid carbonate is for relaxingThe 10-15% of Batan acid, the 85-90% that the molfraction of sodium acetate is sulbactam.
The factor that affects the stability of sulbactam is mainly the control of production process technology. The preparation method of sulbactamMiddle sodium acetate and sodium acid carbonate are alkaline agent, if alone sodium acetate, the product pH value obtaining is on the low side, and reaction is also insufficient in addition,But its crystal grain obtaining is large, and the crystal grain that alone sodium acid carbonate obtains is little, therefore adopts sodium acetate and carbonic acidThe mixed solution of hydrogen sodium, as alkaline agent, carries out crystallization. Certainly preferably can first add SAS to carry out the cultivation of large nucleus,Add again sodium acid carbonate to continue crystallization and keep output and higher pH value. The ethanol adding taking crystallize out cmpletely asAccurate. Inventor finds that infrared radiation can increase the ionization energy of effects of ion, can accelerate crystallization, suitable irradiation energyEnough promote crystallization, energy is too high, can produce on the contrary many thin crystalline substances.
After stirring 10min in step (two), also can add a small amount of sulbactam crystal, moles hundred of this sulbactam crystalProportion by subtraction is the 0.1-0.5% of the sulbactam that adds.
A kind of pharmaceutical preparation, comprises foregoing pharmaceutical composition.
Pharmaceutical preparation can pharmaceutically acceptable preparation type. Preparation type can be injection, tablet, capsule etc.Deng or load on the carrier that other medically can be used.
Compared with prior art, the invention has the beneficial effects as follows:
1, the present invention adopts the cefoperazone sodium of specific specific rotation and sulbactam to make, can improve medicine stability,Particularly clarity stability, makes the clinical safe medication that is able to.
The clarity good stability of the preparation that 2, cefoperazone sodium sulbactam sodium of the present invention prepares, can be in room temperatureUnder be saved in more than 18 months.
Detailed description of the invention
For making the object, technical solutions and advantages of the present invention clearer, below in conjunction with embodiment, the present invention is doneFurther describe in detail, exemplary embodiment of the present invention and explanation thereof are only for explaining the present invention, and conduct is not to thisThe restriction of invention.
Embodiment 1
A pharmaceutical composition for cefoperazone sodium sulbactam sodium, comprises sulbactam and specific rotation and is the cephalo piperazine of-20 °Ketone sodium, the mass ratio of cefoperazone sodium and sulbactam is 1:1.
Embodiment 2
A pharmaceutical composition for cefoperazone sodium sulbactam sodium, comprises sulbactam and specific rotation and is the cephalo piperazine of-22 °Ketone sodium, the mass ratio of cefoperazone sodium and sulbactam is 1:1.
Embodiment 3
A pharmaceutical composition for cefoperazone sodium sulbactam sodium, comprises sulbactam and specific rotation and is the cephalo piperazine of-24 °Ketone sodium, the mass ratio of cefoperazone sodium and sulbactam is 2:1.
Embodiment 4
A pharmaceutical composition for cefoperazone sodium sulbactam sodium, comprises specific rotation and is sulbactam and the specific rotation of+228 °The cefoperazone sodium that degree is-20 °, the mass ratio of cefoperazone sodium and sulbactam is 1:1.
Embodiment 5
A pharmaceutical composition for cefoperazone sodium sulbactam sodium, comprises specific rotation and is sulbactam and the specific rotation of+223 °The cefoperazone sodium that degree is-22 °, the mass ratio of cefoperazone sodium and sulbactam is 1:1.
Embodiment 6
A pharmaceutical composition for cefoperazone sodium sulbactam sodium, comprises specific rotation and is sulbactam and the specific rotation of+225 °The cefoperazone sodium that degree is-24 °, the mass ratio of cefoperazone sodium and sulbactam is 2:1.
Embodiment 7
The preparation method of cefoperazone sodium is: it is molten that (1) is added to cefoperazone acid acetone at 0-5 DEG C by SAS stirringIn liquid, pH value is controlled at 6.5-6.9; (2) after sodium acetate adds, then solution is warming up to 10-25 degree Celsius, by bicarbonateSodium solution stirs and is added in cefoperazone acid acetone soln, and pH value is controlled at 6.5-6.9; (3) react after complete filtration point three rankSection, the first stage, agitation and dropping entered acetone by filtrate temperature control at 18-20 DEG C, dripped 5-10min; Second stage, 18-20 DEG C is stirredMix 30-60min, after crystal is separated out, continue agitation and dropping acetone, drip 10-15min; Phase III, 10-15 DEG C is stirred 30-60min, finally cleans crystal; Wherein the molfraction of sodium acetate is the 10-15% of cefoperazone acid, sodium acid carbonateMolfraction is the 85-90% of cephalo ketone acid.
In step (3), first stage mixing speed is 300-350r/min, and second stage mixing speed is 200-250r/Min, phase III mixing speed is 100-150r/min.
Wherein the molar fraction of sodium acetate can be 10%, 12% or 15% of cefoperazone acid. Rubbing of sodium acid carbonateYour mark is 85%, 88% or 90% of cefoperazone acid.
The specific rotation of the cefoperazone sodium that the present invention makes is at-20 °～-24 °, and the yield of the cefoperazone sodium making existsMore than 94%, crystal grain is large.
Embodiment 8
The preparation method of sulbactam is: at (one) 20-25 DEG C, sulbactam is added to the mixed of sodium acetate and sodium acid carbonateClose in solution constantly and stir, and to control pH value of solution be 5.5-6.0; (2), after reaction finishes, add ethanol and constantly stir 10minAfter, use infrared radiation 3-5min simultaneously, continue to stir 30-60min and obtain crystal, wherein the molfraction of sodium acid carbonate is for relaxingThe 10-15% of Batan acid, the 85-90% that the molfraction of sodium acetate is sulbactam.
After stirring 10min in step (two), also can add a small amount of sulbactam crystal, moles hundred of this sulbactam crystalProportion by subtraction is the 0.1-0.5% of the sulbactam that adds.
The specific rotation of the sulbactam obtaining is that+223 °～+ 228 °, yield are more than 92.8%, and crystal grain is large.
Embodiment 10
A kind of pharmaceutical preparation, comprises foregoing pharmaceutical composition and pharmaceutically acceptable carrier.
Pharmaceutical preparation can be pharmaceutically acceptable preparation type, as is injection, tablet, capsule etc.
Performance Detection: with accelerating experimental method, investigate pharmaceutical composition and keep in Dark Place and place 0 month, January, 6 at room temperature humidityStability and its related substances in the moon, December, and the stable experiment of clarity of investigating injection agent is (by cefoperazoneSodium and sulbactam sodium be prepared into injection place behind 0 month, January, June, December, 18 months under room temperature, investigate respectively clarity).
Table 1 is filled a prescription:
Experimental result:
The content (%) of table 2 cefoperazone sodium
The content (%) of table 3 sulbactam
| Project | 0 month | January | June | December |
| Embodiment 1 | 99.8 | 99.8 | 99.6 | 99.4 |
| Embodiment 2 | 99.8 | 99.8 | 99.5 | 99.2 |
| Embodiment 3 | 99.9 | 99.8 | 99.6 | 99.4 |
| Embodiment 4 | 99.6 | 99.6 | 99.4 | 99.3 |
| Embodiment 5 | 99.8 | 99.8 | 99.5 | 99.5 |
| Embodiment 6 | 99.8 | 99.8 | 99.6 | 99.5 |
| Comparative example 1 | 99.7 | 99.3 | 98.1 | 96.2 |
| Comparative example 2 | 99.6 | 98.9 | 97.3 | 96.0 |
The content (%) of table 4 related substance
Table 5 clarity
| Project | 0 month | January | June | December | 18 months |
| Embodiment 1 | Clarification | Clarification | Clarification | Clarification | Muddy |
| Embodiment 2 | Clarification | Clarification | Clarification | Clarification | Clarification |
| Embodiment 3 | Clarification | Clarification | Clarification | Clarification | Clarification |
| Embodiment 4 | Clarification | Clarification | Clarification | Clarification | Clarification |
| Embodiment 5 | Clarification | Clarification | Clarification | Clarification | Clarification |
| Embodiment 6 | Clarification | Clarification | Clarification | Clarification | Clarification |
| Comparative example 1 | Clarification | Clarification | Clarification | Muddy | Muddy |
| Comparative example 2 | Clarification | Clarification | Clarification | Muddy | Muddy |
Can find out the good stability of cefoperazone sodium sulbactam sodium of the present invention, cephalo piperazine after 12 months from table 2-table 5The content of ketone sodium still can remain on 99.3%-99.7%, and the content of sulbactam remains on 99.2%-99.5%, related substanceContent is below 0.71%; The cefoperazone sodium of comparative example and the content of sulbactam have all been reduced to below 96.5%,Related substance has reached more than 7.58%; The clarification of the injection that the cefoperazone sodium sulbactam sodium that the present invention makes makesDegree good stability, can at room temperature be saved in more than 18 months.
Be as mentioned above embodiments of the invention. The present invention is not limited to above-mentioned embodiment, and anyone should learnThe structural change of making under enlightenment of the present invention, every have identical or close technical scheme with the present invention, all falls into thisWithin the protection domain of invention.
Claims (10)
1. a pharmaceutical composition for cefoperazone sodium sulbactam sodium, is characterized in that: comprise sulbactam and specific rotation for-The cefoperazone sodium of 20 °～-24 °, the mass ratio of cefoperazone sodium and sulbactam is 1～2:1.
2. pharmaceutical composition according to claim 1, is characterized in that: the specific rotation of cefoperazone sodium be-22 °～-24°。
3. pharmaceutical composition according to claim 3, is characterized in that: the specific rotation of cefoperazone sodium is-24 °, cephaloThe mass ratio of piperazine ketone sodium and sulbactam is 2:1.
4. pharmaceutical composition according to claim 1, is characterized in that: the specific rotation of sulbactam be+223 °～+228°。
5. pharmaceutical composition according to claim 4, is characterized in that: the specific rotation of sulbactam be+223 °～+225°。
6. according to the pharmaceutical composition described in claim 4 or 5, it is characterized in that: the preparation method of sulbactam is: (one)At 20-25 DEG C, sulbactam is added in the mixed solution of sodium acetate and sodium acid carbonate and constantly stir, and control reaction solution pHFor 5.5-6.0; (2) after reaction finishes, add ethanol and constantly stir after 10min, using infrared radiation 3-5min simultaneously, continuingThe continuous 30-60min that stirs obtains crystal, the 10-15% that wherein molfraction of sodium acetate is sulbactam, sodium acid carbonate moleUmber is the 85-90% of sulbactam.
7. pharmaceutical composition according to claim 6, is characterized in that: after stirring 10min in step (two), also can addA small amount of sulbactam crystal, the molar percentage of this sulbactam crystal is the 0.1-0.5% of the sulbactam that adds.
8. according to the pharmaceutical composition described in claim 1-5 any one, it is characterized in that: the preparation method of cefoperazone sodiumFor: (1) is stirred SAS and is added in cefoperazone acid acetone soln at 0-5 DEG C, and pH value is controlled at 6.5-6.9; (2) vinegarAfter acid sodium adds, then solution is warming up to 10-25 degree Celsius, sodium bicarbonate solution is stirred and is added to cefoperazone acid acetoneIn solution, pH value is controlled at 6.5-6.9; (3) react after complete decolorization filtering, in three stages, the first stage exists filtrate temperature control18-20 DEG C, agitation and dropping enters acetone, drips 5-10min; Second stage, 18-20 DEG C is stirred 30-60min, after crystal is separated out,Continue agitation and dropping acetone, drip 10-15min; Phase III, 10-15 DEG C is stirred 30-60min, and filtration washing obtains crystal;Wherein the molal quantity total amount of sodium acetate and sodium acid carbonate and head roar piperazine ketone acid molal quantity equate, the molfraction of sodium acetate is headThe 10-15% of spore piperazine ketone acid, the molfraction of sodium acid carbonate is the 85-90% of cephalo ketone acid.
9. pharmaceutical composition according to claim 8, is characterized in that: in step (3), first stage mixing speed is300-350r/min, second stage mixing speed is 200-250r/min, phase III mixing speed is 100-150r/min.
10. a pharmaceutical preparation, is characterized in that, comprises pharmaceutical composition and pharmacy as described in claim 1-5 any oneUpper acceptable carrier.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610006351.2A CN105596345B (en) | 2016-01-04 | 2016-01-04 | Preparation method for drug composition of cefoperazone sodium and sulbactam sodium |
| PCT/CN2016/078921 WO2017117880A1 (en) | 2016-01-04 | 2016-04-11 | Pharmaceutical composition of cefoperazone sodium and sulbactam sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610006351.2A CN105596345B (en) | 2016-01-04 | 2016-01-04 | Preparation method for drug composition of cefoperazone sodium and sulbactam sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105596345A true CN105596345A (en) | 2016-05-25 |
| CN105596345B CN105596345B (en) | 2017-05-17 |
Family
ID=55977081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610006351.2A Active CN105596345B (en) | 2016-01-04 | 2016-01-04 | Preparation method for drug composition of cefoperazone sodium and sulbactam sodium |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN105596345B (en) |
| WO (1) | WO2017117880A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309448A (en) * | 2016-08-24 | 2017-01-11 | 南昌立健药业有限公司 | Novel cefoperazone sodium and sulbactam sodium pharmaceutical composition for injection |
| CN106432277A (en) * | 2016-09-21 | 2017-02-22 | 陕西顿斯制药有限公司 | Cefoperazone sodium compound and sulbactam sodium compound prepared with strong-field coupling crystallization technology as well as prepared composition |
| CN106432273A (en) * | 2016-09-07 | 2017-02-22 | 陕西顿斯制药有限公司 | Cefoperazone sodium compound prepared by using fluid mechanics principle and preparation comprising cefoperazone sodium compound |
| CN114163308A (en) * | 2021-12-13 | 2022-03-11 | 苏州东瑞制药有限公司 | Method for recycling and preparing pharmaceutical grade absolute ethyl alcohol by utilizing sulbactam sodium mother liquor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249092A (en) * | 2008-04-10 | 2008-08-27 | 黄芝芳 | Infection contamination resistance pharmaceutical combination containing optimum proportioning cefoperazone natrium and sulbactam sodium and method of preparing the same |
| CN104644629A (en) * | 2015-01-27 | 2015-05-27 | 华北制药股份有限公司 | Ampicillin sodium sulbactam sodium preparation for injection and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100494165C (en) * | 2006-03-29 | 2009-06-03 | 宝山钢铁股份有限公司 | Preparation method of D-para-hydroxybenzol gylcine |
| CN104327099A (en) * | 2014-09-29 | 2015-02-04 | 联合康兴（北京）医药科技有限公司 | Cefoperazone sodium compound entity, composition and application |
-
2016
- 2016-01-04 CN CN201610006351.2A patent/CN105596345B/en active Active
- 2016-04-11 WO PCT/CN2016/078921 patent/WO2017117880A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249092A (en) * | 2008-04-10 | 2008-08-27 | 黄芝芳 | Infection contamination resistance pharmaceutical combination containing optimum proportioning cefoperazone natrium and sulbactam sodium and method of preparing the same |
| CN104644629A (en) * | 2015-01-27 | 2015-05-27 | 华北制药股份有限公司 | Ampicillin sodium sulbactam sodium preparation for injection and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309448A (en) * | 2016-08-24 | 2017-01-11 | 南昌立健药业有限公司 | Novel cefoperazone sodium and sulbactam sodium pharmaceutical composition for injection |
| CN106432273A (en) * | 2016-09-07 | 2017-02-22 | 陕西顿斯制药有限公司 | Cefoperazone sodium compound prepared by using fluid mechanics principle and preparation comprising cefoperazone sodium compound |
| CN106432277A (en) * | 2016-09-21 | 2017-02-22 | 陕西顿斯制药有限公司 | Cefoperazone sodium compound and sulbactam sodium compound prepared with strong-field coupling crystallization technology as well as prepared composition |
| CN114163308A (en) * | 2021-12-13 | 2022-03-11 | 苏州东瑞制药有限公司 | Method for recycling and preparing pharmaceutical grade absolute ethyl alcohol by utilizing sulbactam sodium mother liquor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105596345B (en) | 2017-05-17 |
| WO2017117880A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105596345A (en) | Drug composition of cefoperazone sodium and sulbactam sodium | |
| CN102924483B (en) | Ceftazidime crystal compound, preparation method of compound and pharmaceutical composition of compound in sterile mixed powder form | |
| CN104086569A (en) | Preparation method of cefotaxime sodium | |
| CN102659818A (en) | Hydrochloric acid cefotiam crystalline compound, preparation method thereof and medicine combination containing compound | |
| CN102838622A (en) | Preparation method of stable cefuroxime sodium | |
| WO2021227146A1 (en) | N-[8-(2-hydroxybenzoyl)amino]monopotassium octanoate crystal compound, and preparation method therefor and use thereof | |
| CN106309448A (en) | Novel cefoperazone sodium and sulbactam sodium pharmaceutical composition for injection | |
| CN102643255A (en) | Andrographolide compound | |
| CN105520942A (en) | Ampicillin sodium and sulbactam sodium pharmaceutical composition | |
| CN102617643B (en) | Riboflavin sodium phosphate compound | |
| CN104644637A (en) | Piperacillin sodium tazobactam sodium preparation for injection and preparation method thereof | |
| CN104958318A (en) | Medicinal sulbactam sodium composition for treating infectious diseases | |
| CN100484526C (en) | Compounding method of cefpirome sulfate raw material and uses thereof | |
| CN103145735A (en) | Cefmenoxime hydrochloride compound for injection and pharmaceutical composition thereof | |
| CN109096129A (en) | A kind of preparation method of L-carnitine-L-tartrate | |
| CN105693793B (en) | A kind of Ribavirin compound and its pharmaceutical composition | |
| CN101919816B (en) | Tigecycline-containing sterile packaged preparation for injection | |
| CN101200473B (en) | Method for preparing cefepime dihydrochloride monohydrate crystal | |
| CN104844522B (en) | Morpholine nitre azoles crystal and preparation method thereof and medical usage | |
| WO2017140073A1 (en) | Cefathiamidine novel crystal compound using particle process crystal product molecular assembly and morphology optimisation technology and formulation thereof | |
| CN104844624B (en) | A kind of cefoperazone sodium sulbactam sodium eutectic and composition and method of making the same | |
| CN104817557B (en) | A kind of stable crystal form of moxifloxacin hydrochloride and preparation method thereof | |
| CN109516991B (en) | Tofacitinib citrate crystal form compound and preparation method thereof | |
| CN103483181B (en) | A kind of Calcium zinc gluconate compound | |
| CN112300197A (en) | Preparation method of oxacillin sodium and oxacillin sodium for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |